GleamWall
中文EN

CMMB Chemomab Therapeutics Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1534248 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY35.5%
TTM EPS YoY-53.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-69.5%
ROA-58.5%
ROIC (approx.)-1,446.2%
Asset turnover—

Leverage & solvency

Liabilities / assets10.7%
Debt / equity0.00x
Current ratio9.08x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.24x
Accruals ratio13.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q22025-06-302025Q12025-03-312024Q22024-06-302024Q12024-03-312023Q22023-06-302023Q12023-03-312022Q4*2022-12-312022Q32022-09-30
Income statement
Revenue————————
R&D expense——$2.93M—$5.02M$6.89M$5.89M$5.42M
SG&A expense——$840,000—$3.17M$2.16M$2.75M$2.89M
Pretax income——-$3.63M—-$7.94M-$8.73M-$8.26M-$8.08M
Income tax——$0—$34,000$21,000$10,000$0
Net income-$2.06M-$3.32M-$3.63M-$3.87M-$7.97M-$8.75M-$8.27M-$8.08M
EPS (basic)——0.01—0.040.04—0.04
EPS (diluted)——0.01—0.040.04—0.04
Weighted avg. shares (diluted)——286.08M—221.67M221.00M—228.77M
Balance sheet
Cash & equivalents$5.45M—$5.11M—$10.46M$20.77M$13.60M$10.74M
Current assets$10.61M—$13.46M—$27.70M$33.78M$41.74M$48.73M
PP&E, net$217,000—$276,000—$338,000$352,000$367,000$380,000
Total assets$11.13M—$14.54M—$28.85M$35.01M$43.06M$50.22M
Current liabilities$1.43M—$4.31M—$6.83M$7.00M$6.75M$5.48M
Total liabilities$1.43M—$4.56M—$6.86M$7.06M$6.84M$5.59M
Shareholders' equity$9.70M$10.39M$9.98M$13.33M$21.99M$27.95M$36.22M$44.62M
Shares outstanding413.85M—287.18M—248.06M232.64M232.64M229.02M
Cash flow statement
Operating cash flow————-$7.49M-$7.19M-$5.70M-$5.25M
Capital expenditure————$2,000$1,000$1,000$42,000
Free cash flow————-$7.49M-$7.19M-$5.70M-$5.30M
Investing cash flow————-$4.27M$14.43M$9.35M$6.07M
Financing cash flow————$1.37M$0-$869,000$39,000
Depreciation & amortization————$16,000$16,000$14,000$17,000
Stock-based compensation————$639,000$484,000$740,000$836,000

Free plan shows the latest 8 periods; Pro shows all 22 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.